Article Sidebar

pdf
Date Published: 31/07/2024
Abstract Views: 31
Views pdf: 15
DOI: https://doi.org/10.55046/vjrnm.55.1175.2024
Issue
No. 55 (2024)
Section
Scientific research
How to Cite
Mai, T. Q., Pham, L. S., Tran, T. H., Chau, Q. A., & Nguyễn Quang, T. (2024). EVALUATED THE RELATIONSHIP BETWEEN THE PROGNOSTIC VALUE OF PET/CT AND RESPONSE AFTER CONCURRENT CHEMORADIOTHERAPY IN PATIENTS WITH INOPERABLE STAGE III ESOPHAGEAL CANCER. Vietnamese Journal of Radiology and Nuclear Medicine, 55, 53-61. https://doi.org/10.55046/vjrnm.55.1175.2024

EVALUATED THE RELATIONSHIP BETWEEN THE PROGNOSTIC VALUE OF PET/CT AND RESPONSE AFTER CONCURRENT CHEMORADIOTHERAPY IN PATIENTS WITH INOPERABLE STAGE III ESOPHAGEAL CANCER

Mai Thi Quynh1, Pham Lam Son2, Tran The Hoang1, Chau Quynh Anh1, Toàn Nguyễn Quang3,
1 Department of Human Medicine, Hanoi Medical University
2 Department of Human Medicine, K Hospital
3 Bv K

Main Article Content

Abstract

Purpose :This study evaluated the relationship between the prognostic value of PET/CT and response after concurrent chemoradiotherapy (CCRT) in patients with inoperable stage III esophageal cancer.


Methods :We analyzed retrospective and prospective descriptive study of 48 patients with stage III squamous esophageal cancer (T1,2N2M0 hoặc T3,N1,2,M0)  who underwent PET/CT scan to calculate values (SUVmax,MTV,TLG) of the esophageal tumor lesion, then received CCRT at K hospital from January 2023 to June 2024. Longitudinal monitoring of treatment and post-treatment to evaluated the relationship between PET/CT values and prognosis based on disease-free survival (PFS) and overall survival (OS).


 


Results: Research group was 100% male, average age 61,25± 6,67. History of smoking and alcohol abuse 81.25%. The most common location tumor is the middle third (45.8%), two segments of the esophagus (22.9%), and rarely the upper third (10.4%). Pre-treatment period T1,2N2 (43.8%) and T3,N1,2 (56.3%). ROC curve analysis for PET/CT parameters related to cT3 stage corresponding SUVmax > 18.5 g/mL (sensitivity(se): 51.9%, specificity(sp): 76.2%, p < 0.01) , TLG > 181.5 g (se: 70 %, sp: 95.6%, p < 0.001), MTV > 25.5 cm3 (se: 66.7%, sp: 99 %, p < 0.001). Patients received CCRT with radiotherapy dose 50.4 (83.3%), chemical regimens: FOLFOX (56.3%), XELOX (35.4%) and CF (8%). The average follow-up time of the study group was 9.6 months (range 3.02-18.2). After treatment, 36 patients (75%) had disease progression. The significant difference in disease-free survival (PFS) after 12 months of the cT1,2 and cT3 groups was 33.4% and 22.2%, respectively (p<0.05). SUVmax < 18.5 g/mL, MTV < 25.5  cm3 and TLG <181.5 g had a good prognosis with PFS (p<0.05, p<0.001 and p<0.01, respectively). However, there was no significant difference in the SUVmax, MTV, TLG  with the OS of the research group.


Conclusion: T stage and esophageal tumor parameters on PET/CT are meaningful in predicting prognosis and assessing response after concurrent CCRT in patients with inoperable stage III esophageal cancer.

Keywords

Esophageal cancer, PET/CT, concurrent chemoradiotherapy, prognosis, survival.

Article Details

References

1. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 74(3), 229-263.
2. Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med. 2012;53(6):864-871. doi:10.2967/jnumed.111.1015681
3. Meyers BF, Downey RJ, Decker PA, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg. 2007;133(3):738-745. doi:10.1016/j.jtcvs.2006.09.079
4. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction - PubMed. Accessed January 27, 2024. https://pubmed.ncbi.nlm.nih.gov/16966684/
5. Li Y, Zschaeck S, Lin Q, Chen S, Chen L, Wu H. Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation. Radiat Oncol. 2019;14(1):35. doi:10.1186/s13014-019-1236-x
6. Lee, S., Choi, Y., Park, G., Jo, S., Lee, S. S., Park, J., & Shim, H. K. (2021). 18F-FDG PET/CT parameters for predicting prognosis in esophageal cancer patients treated with concurrent chemoradiotherapy. Technology in Cancer Research & Treatment, 20, 15330338211024655.
7. Yin, H., Li, D., Zhu, C., Wang, M., & Wei, N. (2018). Factors relevant to the prognosis of patients with esophageal cancer who received intensity-modulated radiotherapy. Thoracic Cancer, 9(10), 1215-1219.
8. Lin, Jolinta, Seth Kligerman, Rakhi Goel, Payam Sajedi, Mohan Suntharalingam, and Michael D. Chuong. “Stateof-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment.” Journal of gastrointestinal oncology 6, no. 1 (2015): 3. 9. Kim, K., Kim, S. J., Kim, I. J., Pak, K., & Kim, H. (2012). Prognostic value of metabolic volume measured by F-18 FDG PET-CT in patients with esophageal cancer. Thoracic Cancer, 3(3), 255-261.
10. Borggreve, A. S., Goense, L., van Rossum, P. S., Heethuis, S. E., van Hillegersberg, R., Lagendijk, J. J., ... & Meijer, G. J. (2020). Preoperative prediction of pathologic response to neoadjuvant chemoradiotherapy in patients with esophageal cancer using 18F-FDG PET/CT and DW-MRI: a prospective multicenter study. International Journal of Radiation Oncology* Biology* Physics, 106(5), 998-1009.
11. Omloo JM, van Heijl M, Hoekstra OS, van Berge Henegouwen MI, van Lanschot JJ, Sloof GW. FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol. 2011 Nov;18(12):333852. doi: 10.1245/s10434-011-1732-1. Epub 2011 May 3. PMID: 21537872; PMCID: PMC3192273.